

## Manufacturers' Forum

### **ANNOUNCEMENT**

# NorthStar HealthCare Consulting Georgia Department of Community Health

On behalf of the Georgia Department of Community Health (DCH) and in service to the Georgia Medicaid Fee-for-Service (FFS) Drug Utilization Review Board (DURB), NorthStar HealthCare Consulting (NHC), in conjunction with OptumRx, announces the Manufacturers' Forum occurring Tuesday, October 3, 2017, with an overflow day on Wednesday, October 4, 2017 *only* if needed.

Date: Tuesday, October 3, 2017 from 9am-5pm EST

Wednesday, October 4, 2017 from 9am-5pm EST (overflow day only if needed)

Location: NorthStar HealthCare Consulting

1121 Alderman Drive, Suite 112

Alpharetta, GA 30005

Appointments: The Manufacturers' Forum is by appointment only. Appointments may be requested and will be scheduled after the Drugs Under Review are posted to the DCH website at <a href="http://dch.georgia.gov/2017-durb-meeting-information">http://dch.georgia.gov/2017-durb-meeting-information</a> approximately 30 days prior to the Forum. Manufacturers with drugs up for review at the current DURB meeting will be granted preference when seeking appointments. All requests for appointments must be made in writing to <a href="mailto:GAMedicaid@nhc-Ilc.com">GAMedicaid@nhc-Ilc.com</a> and include the drug name. New drug entities are generally not reviewed by the DURB until the drug has been on the market for at least 6 months.

### **Guidelines for Participation:**

- To ensure equitable treatment of all manufacturers, individual manufacturer participation shall be limited to one 30-60 minute time segment per Forum. The presentation shall be limited to approximately 20-40 minutes with 10-20 minutes for questions and answers.
- Manufacturer presentations may be audio-recorded for review after the Forum.
- For new drugs, manufacturers are highly encouraged to present all clinical information pertinent and relevant to current NHC clinical presentations to the DURB, to DCH drug benefit plan design and to other drugs within the class.
- For existing drugs, manufacturers are highly encouraged to present *new* clinical information since the drug was last reviewed by the DURB, especially clinical information related to comparisons of other drugs within the class.
- An electronic <u>one-page</u> summary (front only, font 10, not including references) of each drug presentation, <u>factually based</u>, in a stand-alone, user-friendly document should be provided one week prior to the presentation via email to <u>GAMedicaid@nhc-llc.com</u>. Please include a pronunciation guide of the drug's brand and generic names. The one-page summary will be provided to the DURB members.

#### **Comments and Inquiries:**

- Manufacturers with comments or inquiries related to Georgia Medicaid FFS <u>Preferred Drug</u> <u>List, Prior Authorization Criteria, Manufacturers' Forum or DURB</u> should submit these in writing to <u>GAMedicaid@nhc-Ilc.com</u>.
- Manufacturers with comments or inquiries related to Georgia Medicaid FFS <u>supplemental</u> <u>rebates</u> should submit these in writing to <u>pba\_gaoffers@changehealthcare.com</u>.
- Manufacturers with comments or inquiries related to Georgia Medicaid FFS <u>claims processing</u> or <u>drug benefit plan design</u> should submit these in writing to <u>Tami.Sweat@optum.com</u>.